Cutting edge liver health management program

    Best practices for revitalizing liver

    Practice impact calculator

    Please fill in all fields below:

    Our Healthy Program

    Find out more about the program, its outcomes and the benefits it has provided to patients and physicians.

    Woman playing with an appleWoman playing with an appleWoman playing with an apple

    Check out our recommended articles

    Trending topics on liver health

    Obese man with measuring tape

    Obesity Has Reached Crisis Proportions

    Understanding the Alarming Scale of the Obesity Problem

    Clinician using microscope

    Latest NAFLD Practice guidelines by AGA

    Clinical care Pathway for the risk stratification and management of patients with NAFLD

    FibroScan device

    A Liver Scan on the Drive-Thru Menu?

    Non-invasive liver tests track lifestyle changes for better liver health

    Surfing the NASH Tsunami Podcast

    Expanding Benefits in FibroScan® Use and Integrating Digital Tools

    Navigating the Future of Liver Health: FibroScan®, Data Integration, and Patient Care

    Meet us at these upcoming events

    EASL SLD Summit 2023

    EASL SLD Summit 2023

    Prague, Czechia

    The EASL SLD Summit provides high quality, independent and state-of-the-art educational and scientific updates on Steatotic Liver Disease (SLD). In September 2023 more than 600 clinicians, researchers, PPH specialists, nurses, allied health professionals, and patient representatives will meet in Prague.

    AASLD: The liver meeting 2023

    AASLD: The liver meeting 2023

    Boston, MA

    The Liver Meeting brings together clinicians, associates, and scientists from around the world to exchange information on the latest research, discuss new developments in liver treatment and transplantation, and network with leading experts in the field of hepatology.

    NASH-TAG 2024

    NASH-TAG 2024

    Park City, UT

    The NASH-TAG Conference is designed to bring together clinicians and researchers in academia and the pharmaceutical industry for a focused interactive educational update highlighting the most relevant advances and challenges in the diagnosis and therapy of NASH and liver fibrosis.

    Today 25-30% of the general population are estimated to have NAFLD, most being undetected. With the expected rise of NAFLD prevalance by 2030, NASH is projected to DOUBLE. 
    Current clinical guideliness recommend:A NAFLD screening should be part of a routine work-up in high-risk patients! Patients having Type 2 diabetes, obesity, and/or metabolic syndrome.

    Two Companies, One Mission

    Providing a complementary approach to managing and monitoring

    chronic liver deseases, which may lead to improve patient outcomes.


    Innovation dedicated to liver health, offering FibroScan®,

    the leading non-invasive liver testing solution.

    1Asset 10

    The leader in digital therapeutics providing a scalable

    NAFLD clinical service line.